ENG
Acute Lymphocytic Leukemia Therapeutics Market: Global Industry Analysis and Forecast (2024-2030) by Therapy, Type, and Region
The Acute Lymphocytic Leukemia Therapeutics Market size was valued at US$ 3.28 Billion in 2023 and the Acute Lymphocytic Leukemia Therapeutics revenue is expected to grow at 4.1% through 2024 to 2030, reaching nearly US$ 4.35
Billion.
Format : PDF | Report ID : SMR_281
Acute Lymphocytic Leukemia Therapeutics Market Definition & Overview:
The increased incidence of acute lymphoblastic leukaemia (ALL) over the world is one of the primary factors driving this market's growth. Each year, around 1.7 per 100,000 men and women are diagnosed with the disease. According to the American Cancer Institute, there will be roughly 5,930 new cases of ALL in 2019, including 3,280 men and 2,650 females. Also, it is anticipated that the number of cases of ALL in Asia-Pacific and South American countries would vary from 0.4 to 2 per 100,000 by 2020. Sement analysis of report on the Acute Lymphocytic Leukemia Therapeutics Market is provided by therapy, type and region.
To get more Insights: Request Free Sample Report
Acute Lymphocytic Leukemia Therapeutics Market Dynamics:
The global acute lymphocytic leukemia therapeutics market is expected to grow due to increased government and pharmaceutical organization activities to raise awareness about the condition. Secondly, the market is expected to grow due to developments in technology for treating illnesses that have been induced by increased expenditures made by manufacturers.
The introduction of new pharmaceuticals for acute lymphocytic leukemia therapeutics, as well as technology improvements in the healthcare sector, are expected to boost the growth of the acute lymphocytic leukemia therapeutics market during the forecast period. Besides that, the "Therapeutically Applicable Research to Generate Effective Treatments (TARGET)" initiative and the "Childhood Cancer Targeted Therapeutics Workshop" has introduced several programs and collaborated with several research groups from around the world, including St. Jude Children's Research Hospital and the University of New Mexico, to provide patients with early diagnosis and better leukaemia treatment. In the forecast period, these factors are expected to drive market growth.
Acute Lymphocytic Leukemia Therapeutics Market Segment Analysis:
By Therapy, Chemotherapy is expected to be the most popular type of treatment in the acute lymphocytic leukemia therapeutics market. Chemotherapy is the principal treatment for persons with acute lymphoblastic leukaemia (ALL), according to the American Cancer Society, and it comprises three phases: remission, consolidation, and maintenance. Chemotherapy is the employment of cytotoxic medicines to kill cancer cells.
Some of the medications used in ALL chemotherapy include amsacrine (NordMedica), cyclophosphamide (Baxter), and cytarabine (Pfizer). These medications are provided by global pharmaceutical companies such as Baxter International and Pfizer. According to a 2019 study by the Leukemia & Lymphoma Society, ALL is the most frequent malignancy in children, adolescents, and young people under the age of 20, accounting for 19.8% of all cancer diagnoses in this age range. As a result of the increased frequency of ALL, particularly among youngsters, the market for chemotherapy is likely to grow.
By Type, in the acute lymphocytic leukemia therapeutics market, hospital pharmacies held the biggest share. This is due to an increase in the number of patients who require treatment in hospitals with modern infrastructure and suitable amenities. In addition, the expanding number of hospitals, combined with acceptable reimbursement rules, is driving this market forward.
Acute Lymphocytic Leukemia Therapeutics Market Regional Insights:
Because of the increased number of occurrences of this illness in the region as a result of hereditary factors, environmental factors, and radiation, North America is likely to dominate this market. Additionally, the presence of multinational corporations, as well as good government regulations, well-established healthcare infrastructure, and favourable government policies make this area dominant in this sector.
During the forecast period, the Asia-Pacific Acute Lymphocytic Leukemia Therapeutics Market is expected to have the quickest CAGR of 6.3 per cent. In the Asia-Pacific region, China and India are likely to be the fastest-growing leukaemia markets. Increasing R&D investment, a huge pool of patients, and expanding government financing are some of the primary driving drivers for the leukaemia therapeutics market in emerging countries.
The objective of the report is to present a comprehensive analysis of the Acute Lymphocytic Leukemia Therapeutics Market to the stakeholders in the industry. The report provides trends that are most dominant in the Acute Lymphocytic Leukemia Therapeutics Market and how these trends will influence new business investments and market development throughout the forecast period. The report also aids in the comprehension of the ALLT market dynamics and competitive structure of the market by analyzing market leaders, market followers, and regional players.
The qualitative and quantitative data provided in the Acute Lymphocytic Leukemia Therapeutics Market report is to help understand which market segments, regions are expected to grow at higher rates, factors affecting the market, and key opportunity areas, which will drive the industry and market growth through the forecast period. The report also includes the competitive landscape of key players in the industry along with their recent developments in the Acute Lymphocytic Leukemia Therapeutics Market. The report studies factors such as company size, market share, market growth, revenue, production volume, and profits of the key players in the ALLT Market.
The report provides Porter's Five Force Model, which helps in designing the business strategies in the market. The report helps in identifying how many rivals are existing, who they are, and how their product quality is in the Market. The report also analyses if the Acute Lymphocytic Leukemia Therapeutics Market is easy for a new player to gain a foothold in the market, do they enter or exit the market regularly if the market is dominated by a few players, etc.
Acute Lymphocytic Leukemia Therapeutics Market Scope:
|
Acute Lymphocytic Leukemia Therapeutics Market |
|
|
Market Size in 2023 |
USD 3.28 Bn. |
|
Market Size in 2030 |
USD 4.35 Bn. |
|
CAGR (2024-2030) |
4.1% |
|
Historic Data |
2018-2022 |
|
Base Year |
2023 |
|
Forecast Period |
2024-2030 |
|
Segment Scope |
by Therapy
|
|
By Type
|
|
|
Regional Scope |
North America- United States, Canada, and Mexico Europe – UK, France, Germany, Italy, Spain, Sweden, Austria, and Rest of Europe Asia Pacific – China, India, Japan, South Korea, Australia, ASEAN, Rest of APAC Middle East and Africa - South Africa, GCC, Egypt, Nigeria, Rest of the Middle East and Africa South America – Brazil, Argentina, Rest of South America |
Acute Lymphocytic Leukemia Therapeutics Market Players:
- Erytech Pharma (France)
- Spectrum Pharmaceuticals, Inc. (United States)
- Pfizer, Inc. (United States)
- Sigma-Tau s.p.a. (Italy)
- Genzyme Corporation (United States)
- Amgen, Inc. (United States)
- Bristol-Myers Squibb Company (United States)
- Erytech Pharma (France)
- Leadiant Biosciences, Inc. (Italy)
- Novartis AG (Switzerland)
- Rare Disease Therapeutics, Inc. (United States)
- Sanofi (France)
- Spectrum Pharmaceuticals, Inc (United States)
- Takeda Pharmaceutical Company Limited. (Japan)
Frequently Asked Questions
The worldwide acute lymphocytic leukaemia therapeutics pharmaceuticals market is expected to grow due to increased government and pharmaceutical organization activities to raise awareness about the condition.
Because of the increased number of occurrences of this illness in the region as a result of hereditary factors, environmental factors, and radiation, North America is likely to dominate this market.
Increasing R&D investment, a huge pool of patients, and expanding government financing are some of the primary driving drivers for the leukaemia therapeutics market in the region.
Erytech Pharma, Spectrum Pharmaceuticals, Inc., Pfizer, Inc., Sigma-Tau s.p.a., Genzyme Corporation, and Amgen, Inc.
Chapter 1 Scope of the Report
Chapter 2 Research Methodology
2.1. Research Process
2.2. Global Acute Lymphocytic Leukemia Therapeutics Market: Target Audience
2.3. Global Acute Lymphocytic Leukemia Therapeutics Market: Primary Research (As per Client Requirement)
2.4. Global Acute Lymphocytic Leukemia Therapeutics Market: Secondary Research
Chapter 3 Executive Summary
Chapter 4 Competitive Landscape
4.1. Market Share Analysis, By Region, 2023-2030(In %)
4.1.1.1. North America Market Share Analysis, By Value, 2023-2030 (In %)
4.1.1.2. Europe Market Share Analysis, By Value, 2023-2030 (In %)
4.1.1.3. Asia Pacific Market Share Analysis, By Value, 2023-2030 (In %)
4.1.1.4. South America Market Share Analysis, By Value, 2023-2030 (In %)
4.1.1.5. Middle East and Africa Market Share Analysis, By Value, 2023-2030 (In %)
4.2. Market Dynamics
4.2.1. Market Drivers
4.2.2. Market Restraints
4.2.3. Market Opportunities
4.2.4. Market Challenges
4.2.5. PESTLE Analysis
4.2.6. PORTERS Five Force Analysis
4.2.7. Value Chain Analysis
4.3. Global Acute Lymphocytic Leukemia Therapeutics Market Segmentation Analysis, 2023-2030 (Value US$ MN)
4.3.1.1. Global Market Share Analysis, By Therapy, 2023-2030 (Value US$ MN)
4.3.1.1.1.Chemotherapy
4.4.1.1.1.1 Hyper-CVAD
4.4.1.1.1.2 CALGB 8811 regimen
4.4.1.1.1.3 Linker regimen
4.4.1.1.1.4 Nucleoside Metabolic Inhibitors
4.4.1.1.1.5 Oncaspar
4.3.1.1.2.Targeted therapy
4.3.1.1.3.Radiation Therapy
4.3.1.1.4.Stem cell transplantation
4.3.1.2. Global Market Share Analysis, By Type, 2023-2030 (Value US$ MN)
4.3.1.2.1.Philadelphia chromosome
4.3.1.2.2.Precursor B-cell ALL
4.3.1.2.3.T-cell ALL
4.4. North America Acute Lymphocytic Leukemia Therapeutics Market Segmentation Analysis, 2023-2030 (Value US$ MN)
4.4.1.1. North America Market Share Analysis, By Therapy, 2023-2030 (Value US$ MN)
4.4.1.1.1. Chemotherapy
4.4.1.1.1.6 Hyper-CVAD
4.4.1.1.1.7 CALGB 8811 regimen
4.4.1.1.1.8 Linker regimen
4.4.1.1.1.9 Nucleoside Metabolic Inhibitors
4.4.1.1.1.10 Oncaspar
4.4.1.1.2.Targeted therapy
4.4.1.1.3.Radiation Therapy
4.4.1.1.4.Stem cell transplantation
4.4.1.2. North America Market Share Analysis, By Type, 2023-2030 (Value US$ MN)
4.4.1.2.1.Philadelphia chromosome
4.4.1.2.2.Precursor B-cell ALL
4.4.1.2.3.T-cell ALL
4.4.1.3. North America Market Share Analysis, By Country, 2023-2030 (Value US$ MN)
4.4.1.3.1.US
4.4.1.3.2.Canada
4.4.1.3.3.Mexico
4.5. Europe Acute Lymphocytic Leukemia Therapeutics Market Segmentation Analysis, 2023-2030 (Value US$ MN)
4.5.1.1. Europe Market Share Analysis, By Therapy, 2023-2030 (Value US$ MN)
4.5.1.2. Europe Market Share Analysis, By Type, 2023-2030 (Value US$ MN)
4.5.1.3. Europe Market Share Analysis, By Country, 2023-2030 (Value US$ MN)
4.5.1.3.1.UK
4.5.1.3.2.France
4.5.1.3.3.Germany
4.5.1.3.4.Italy
4.5.1.3.5.Spain
4.5.1.3.6.Sweden
4.5.1.3.7.Austria
4.5.1.3.8.Rest Of Europe
4.6. Asia Pacific Acute Lymphocytic Leukemia Therapeutics Market Segmentation Analysis, 2023-2030 (Value US$ MN)
4.6.1.1. Asia Pacific Market Share Analysis, By Therapy, 2023-2030 (Value US$ MN)
4.6.1.2. Asia Pacific Market Share Analysis, By Type, 2023-2030 (Value US$ MN)
4.6.1.3. Asia Pacific Market Share Analysis, By Country, 2023-2030 (Value US$ MN)
4.6.1.3.1.China
4.6.1.3.2.India
4.6.1.3.3.Japan
4.6.1.3.4.South Korea
4.6.1.3.5.Australia
4.6.1.3.6.ASEAN
4.6.1.3.7.Rest Of APAC
4.7. South America Acute Lymphocytic Leukemia Therapeutics Market Segmentation Analysis, 2023-2030 (Value US$ MN)
4.7.1.1. South America Market Share Analysis, By Therapy, 2023-2030 (Value US$ MN)
4.7.1.2. South America Market Share Analysis, By Type, 2023-2030 (Value US$ MN)
4.7.1.3. South America Market Share Analysis, By Country, 2023-2030 (Value US$ MN)
4.7.1.3.1.Brazil
4.7.1.3.2.Argentina
4.7.1.3.3.Rest Of South America
4.8. Middle East and Africa Acute Lymphocytic Leukemia Therapeutics Market Segmentation Analysis, 2023-2030 (Value US$ MN)
4.8.1.1. Middle East and Africa Market Share Analysis, By Therapy, 2023-2030 (Value US$ MN)
4.8.1.2. Middle East and Africa Market Share Analysis, By Type, 2023-2030 (Value US$ MN)
4.8.1.3. Middle East and Africa Market Share Analysis, By Country, 2023-2030 (Value US$ MN)
4.8.1.3.1.South Africa
4.8.1.3.2.GCC
4.8.1.3.3.Egypt
4.8.1.3.4.Nigeria
4.8.1.3.5.Rest Of ME&A
Chapter 5 Stellar Competition Matrix
5.1.1. Global Stellar Competition Matrix
5.1.2. North America Stellar Competition Matrix
5.1.3. Europe Stellar Competition Matrix
5.1.4. Asia Pacific Stellar Competition Matrix
5.1.5. South America Stellar Competition Matrix
5.1.6. Middle East and Africa Stellar Competition Matrix
5.2. Key Players Benchmarking
5.2.1. Key Players Benchmarking By Application, Pricing, Market Share, Investments, Expansion Plans, Physical Presence and Presence in the Market.
5.3. Mergers and Acquisitions in Industry
5.3.1. M&A by Region, Value and Strategic Intent
Chapter 6 Company Profiles
6.1. Key Players
6.1.1. Pfizer, Inc.
6.1.1.1. Company Overview
6.1.1.2. Source Portfolio
6.1.1.3. Financial Overview
6.1.1.4. Business Strategy
6.1.1.5. Key Developments
6.1.2. Erytech Pharma
6.1.3. Spectrum Pharmaceuticals, Inc.
6.1.4. Pfizer, Inc.
6.1.5. Sigma-Tau s.p.a.
6.1.6. Genzyme Corporation
6.1.7. Amgen, Inc.
6.1.8. Bristol-Myers Squibb Company
6.1.9. Erytech Pharma
6.1.10. Leadiant Biosciences, Inc.
6.1.11. Novartis AG
6.1.12. Rare Disease Therapeutics, Inc.
6.1.13. Sanofi
6.1.14. Spectrum Pharmaceuticals, Inc
6.1.15. Takeda Pharmaceutical Company Limited.
6.2. Key Findings
6.3. Recommendations
